Identification

Name
Idelalisib
Accession Number
DB09054
Type
Small Molecule
Groups
Approved
Description

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

Structure
Thumb
Synonyms
  • 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one
  • 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one
External IDs
CAL 101 / CAL-101 / CAL101 / GS 1101 / GS-1101 / GS1101
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZydeligTablet100 mgOralGilead Sciences2015-04-21Not applicableCanada
ZydeligTablet, film coated150 mg/1OralGilead Sciences2014-07-23Not applicableUs
ZydeligTablet, film coated100 mgOralGilead Sciences2014-09-18Not applicableEu
ZydeligTablet, film coated100 mg/1OralGilead Sciences2014-07-23Not applicableUs
ZydeligTablet150 mgOralGilead Sciences2015-04-21Not applicableCanada
ZydeligTablet, film coated150 mgOralGilead Sciences2014-09-18Not applicableEu
Categories
UNII
YG57I8T5M0
CAS number
870281-82-6
Weight
Average: 415.432
Monoisotopic: 415.155686391
Chemical Formula
C22H18FN7O
InChI Key
IFSDAJWBUCMOAH-HNNXBMFYSA-N
InChI
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
IUPAC Name
5-fluoro-3-phenyl-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-3,4-dihydroquinazolin-4-one
SMILES
[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1

Pharmacology

Indication

Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Idelalisib specifically inhibits P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.

TargetActionsOrganism
APhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)
inhibitor
Human
Absorption

Following oral administration, the median Tmax was observed at 1.5 hours.

Volume of distribution

23 L

Protein binding

Idelalisib is greater than 84% bound to human plasma proteins with no concentration dependence.

Metabolism

Idelalisib is metabolized by aldehyde oxidase and CYP3A to its major metabolite GS-563117, which is inactive against P110δ. Idelalisib is also metabolized to a minor extent by UGT1A4.

Route of elimination

Following a single dose of 150 mg of [14C] idelalisib, 78% and 14% of the radioactivity was excreted in feces and urine, respectively. GS-563117, idelalisib's major metabolite, accounted for 49% of the radioactivity in the urine and 44% in the feces.

Half life

The terminal elimination half-life is 8.2 hours.

Clearance

14.9 L/hr

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Idelalisib.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Idelalisib.Experimental, Illicit
AbemaciclibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Abemaciclib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Idelalisib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Idelalisib.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Idelalisib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Idelalisib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Idelalisib.Experimental
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Idelalisib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Idelalisib.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Idelalisib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Idelalisib.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Idelalisib.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Idelalisib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Idelalisib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Idelalisib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Idelalisib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Idelalisib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Idelalisib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Idelalisib.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Idelalisib.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Idelalisib.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Idelalisib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Idelalisib.Approved, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Idelalisib.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Idelalisib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Idelalisib.Approved
AmiodaroneThe serum concentration of Idelalisib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Idelalisib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Idelalisib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Idelalisib.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Idelalisib.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Idelalisib.Approved, Investigational, Withdrawn
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Idelalisib.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Idelalisib.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Idelalisib.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Idelalisib is combined with Anthrax immune globulin human.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Idelalisib.Approved, Investigational
ApalutamideThe serum concentration of Idelalisib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Idelalisib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Idelalisib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Idelalisib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Idelalisib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Idelalisib.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Idelalisib.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Idelalisib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Idelalisib.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Idelalisib.Investigational
AtazanavirThe serum concentration of Idelalisib can be increased when it is combined with Atazanavir.Approved, Investigational
AtorvastatinThe risk or severity of adverse effects can be increased when Idelalisib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Idelalisib.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Idelalisib.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Idelalisib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Idelalisib.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Idelalisib.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Idelalisib is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Idelalisib is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Idelalisib.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Idelalisib.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Idelalisib.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Idelalisib.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Idelalisib.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Idelalisib.Approved
BenidipineThe metabolism of Benidipine can be decreased when combined with Idelalisib.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Idelalisib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Idelalisib.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Idelalisib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Idelalisib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Idelalisib.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Idelalisib.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Idelalisib.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Idelalisib.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Idelalisib.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Idelalisib.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Idelalisib.Approved, Investigational
BoceprevirThe serum concentration of Idelalisib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Idelalisib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Idelalisib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Idelalisib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Idelalisib.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Idelalisib.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Idelalisib.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Idelalisib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Idelalisib.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Idelalisib.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Idelalisib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Idelalisib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Idelalisib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Idelalisib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Idelalisib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Idelalisib.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Idelalisib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Idelalisib.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Idelalisib.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Idelalisib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Idelalisib.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Idelalisib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Idelalisib.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Idelalisib.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Idelalisib.Approved, Investigational
CarbamazepineThe serum concentration of Idelalisib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Idelalisib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Idelalisib.Approved, Investigational
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Idelalisib.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Idelalisib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Idelalisib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Idelalisib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Idelalisib.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Idelalisib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Idelalisib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Idelalisib.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Idelalisib.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Idelalisib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Idelalisib.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Idelalisib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Idelalisib.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Idelalisib.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Idelalisib.Approved
ClarithromycinThe serum concentration of Idelalisib can be increased when it is combined with Clarithromycin.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Idelalisib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Idelalisib.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Idelalisib.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Idelalisib.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Idelalisib.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Idelalisib.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Idelalisib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Idelalisib.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Idelalisib.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Idelalisib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Idelalisib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Idelalisib.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Idelalisib.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Idelalisib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Idelalisib.Approved, Illicit
ClozapineThe metabolism of Clozapine can be decreased when combined with Idelalisib.Approved
CobicistatThe serum concentration of Idelalisib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Idelalisib.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Idelalisib.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Idelalisib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Idelalisib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Idelalisib.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Idelalisib.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Idelalisib.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Idelalisib.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Idelalisib.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Idelalisib.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Idelalisib is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Idelalisib.Approved
CurcuminThe serum concentration of Idelalisib can be increased when it is combined with Curcumin.Approved, Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Idelalisib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Idelalisib.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Idelalisib.Experimental
CytarabineThe metabolism of Cytarabine can be decreased when combined with Idelalisib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Idelalisib.Approved
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Idelalisib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Idelalisib.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Idelalisib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Idelalisib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Idelalisib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Idelalisib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Idelalisib.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Idelalisib.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Idelalisib.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Idelalisib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Idelalisib.Approved
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Idelalisib.Approved, Investigational
DelamanidIdelalisib may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Idelalisib.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Idelalisib.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Idelalisib.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Idelalisib.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Idelalisib.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Idelalisib.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Idelalisib.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Idelalisib.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Idelalisib.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Idelalisib.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Idelalisib.Approved, Investigational
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Idelalisib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Idelalisib.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Idelalisib.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Idelalisib.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Idelalisib.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Idelalisib.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Idelalisib.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Idelalisib.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Idelalisib.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Idelalisib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Idelalisib.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Idelalisib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Idelalisib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Idelalisib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Idelalisib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Idelalisib.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Idelalisib.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Idelalisib.Approved, Investigational
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Idelalisib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Idelalisib.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Idelalisib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Idelalisib.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Idelalisib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Idelalisib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Idelalisib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Idelalisib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Idelalisib.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Idelalisib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Idelalisib.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Idelalisib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Idelalisib.Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Idelalisib.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Idelalisib.Approved, Investigational
EbastineThe serum concentration of Ebastine can be increased when it is combined with Idelalisib.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Idelalisib.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Idelalisib.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Idelalisib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Idelalisib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Idelalisib.Approved
EltrombopagThe serum concentration of Idelalisib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Idelalisib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Idelalisib.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Idelalisib.Approved, Investigational
EnzalutamideThe serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Idelalisib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Idelalisib.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Idelalisib.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Idelalisib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Idelalisib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Idelalisib.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Idelalisib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Idelalisib.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Idelalisib.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Idelalisib.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Idelalisib.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Idelalisib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Idelalisib.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Idelalisib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Idelalisib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Idelalisib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Idelalisib.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Idelalisib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Idelalisib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Idelalisib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Idelalisib.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Idelalisib.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Idelalisib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Idelalisib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Idelalisib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Idelalisib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Idelalisib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Idelalisib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Idelalisib.Approved, Investigational
FelbamateThe metabolism of Felbamate can be decreased when combined with Idelalisib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Idelalisib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Idelalisib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Idelalisib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idelalisib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Idelalisib.Approved
FingolimodIdelalisib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Idelalisib.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Idelalisib.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Idelalisib.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Idelalisib.Approved, Vet Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Idelalisib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Idelalisib.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Idelalisib.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Idelalisib.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Idelalisib.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Idelalisib.Approved, Investigational
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Idelalisib.Approved, Vet Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Idelalisib.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Idelalisib.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Idelalisib.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Idelalisib.Approved, Illicit, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Idelalisib.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Idelalisib.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Idelalisib.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Idelalisib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Idelalisib.Approved
FormestaneThe serum concentration of Formestane can be increased when it is combined with Idelalisib.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Idelalisib.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Idelalisib.Approved
FosphenytoinThe serum concentration of Idelalisib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Idelalisib.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Idelalisib.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Idelalisib is combined with G17DT.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Idelalisib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Idelalisib.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Idelalisib.Approved
GI-5005The risk or severity of adverse effects can be increased when Idelalisib is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Idelalisib.Experimental
GlipizideThe metabolism of Glipizide can be decreased when combined with Idelalisib.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Idelalisib.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Idelalisib.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Idelalisib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Idelalisib.Approved, Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Idelalisib.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Idelalisib.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Idelalisib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Idelalisib.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Idelalisib.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Idelalisib is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Idelalisib is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Idelalisib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Idelalisib.Approved, Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Idelalisib is combined with Human rabies virus immune globulin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Idelalisib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Idelalisib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Idelalisib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Idelalisib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Idelalisib.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Idelalisib.Approved, Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Idelalisib resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Idelalisib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Idelalisib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Idelalisib.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Idelalisib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Idelalisib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Idelalisib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Idelalisib.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Idelalisib.Approved
INGN 201The risk or severity of adverse effects can be increased when Idelalisib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Idelalisib is combined with INGN 225.Investigational
IpecacThe metabolism of Ipecac can be decreased when combined with Idelalisib.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Idelalisib.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Idelalisib.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Idelalisib.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Idelalisib.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Idelalisib.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Idelalisib.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Idelalisib.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Idelalisib.Investigational
ItraconazoleThe serum concentration of Idelalisib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Idelalisib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Idelalisib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Idelalisib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Idelalisib.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Idelalisib is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Idelalisib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Idelalisib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Idelalisib.Approved, Investigational
KetoconazoleThe serum concentration of Idelalisib can be increased when it is combined with Ketoconazole.Approved, Investigational
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Idelalisib.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Idelalisib.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Idelalisib.Experimental
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Idelalisib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Idelalisib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Idelalisib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Idelalisib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Idelalisib is combined with Leflunomide.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Idelalisib.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Idelalisib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Idelalisib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Idelalisib.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Idelalisib.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Idelalisib.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Idelalisib.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Idelalisib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Idelalisib.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Idelalisib.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Idelalisib.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Idelalisib.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Idelalisib.Approved
LopinavirThe serum concentration of Idelalisib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Idelalisib.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Idelalisib.Approved
LorpiprazoleThe metabolism of Lorpiprazole can be decreased when combined with Idelalisib.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Idelalisib.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Idelalisib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Idelalisib.Approved, Investigational
LumacaftorThe serum concentration of Idelalisib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Idelalisib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Idelalisib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Idelalisib.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Idelalisib.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Idelalisib.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Idelalisib.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Idelalisib.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Idelalisib.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Idelalisib.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Idelalisib.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Idelalisib.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Idelalisib.Approved, Investigational
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Idelalisib.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Idelalisib.Approved, Vet Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Idelalisib.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Idelalisib.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Idelalisib.Illicit, Withdrawn
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Idelalisib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Idelalisib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Idelalisib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Idelalisib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Idelalisib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Idelalisib.Experimental
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Idelalisib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Idelalisib.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Idelalisib.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Idelalisib.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Idelalisib.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Idelalisib.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Idelalisib.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Idelalisib.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Idelalisib.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Idelalisib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Idelalisib.Approved
MitotaneThe serum concentration of Idelalisib can be decreased when it is combined with Mitotane.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Idelalisib.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Idelalisib.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Idelalisib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Idelalisib.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Idelalisib.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Idelalisib.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Idelalisib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Idelalisib.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Idelalisib.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Idelalisib.Investigational
NefazodoneThe serum concentration of Idelalisib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Idelalisib can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Idelalisib.Approved, Investigational
NevirapineThe serum concentration of Idelalisib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Idelalisib.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Idelalisib.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Idelalisib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Idelalisib.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Idelalisib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Idelalisib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Idelalisib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Idelalisib.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Idelalisib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Idelalisib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Idelalisib.Approved, Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Idelalisib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Idelalisib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Idelalisib.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Idelalisib.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Idelalisib.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Idelalisib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Idelalisib.Experimental, Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Idelalisib.Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Idelalisib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Idelalisib.Approved
OpiumThe metabolism of Opium can be decreased when combined with Idelalisib.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Idelalisib.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Idelalisib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Idelalisib.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Idelalisib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Idelalisib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Idelalisib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Idelalisib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Idelalisib.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Idelalisib.Approved, Investigational
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Idelalisib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Idelalisib.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Idelalisib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Idelalisib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Idelalisib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Idelalisib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Idelalisib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Idelalisib.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Idelalisib.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Idelalisib.Approved, Investigational
PentobarbitalThe serum concentration of Idelalisib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Idelalisib.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Idelalisib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Idelalisib.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Idelalisib.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Idelalisib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Idelalisib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Idelalisib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Idelalisib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Idelalisib.Withdrawn
PhenobarbitalThe serum concentration of Idelalisib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Idelalisib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Idelalisib.Approved, Investigational
PhenytoinThe serum concentration of Idelalisib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Idelalisib.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idelalisib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Idelalisib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Idelalisib.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Idelalisib.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Idelalisib.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Idelalisib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Idelalisib.Approved
PitolisantThe serum concentration of Idelalisib can be decreased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Idelalisib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Idelalisib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Idelalisib.Approved, Investigational
PosaconazoleThe serum concentration of Idelalisib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Idelalisib.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Idelalisib.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Idelalisib.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Idelalisib resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Idelalisib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Idelalisib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Idelalisib.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Idelalisib.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Idelalisib.Approved, Experimental, Investigational
PrimaquineThe metabolism of Primaquine can be decreased when combined with Idelalisib.Approved
PrimidoneThe serum concentration of Idelalisib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Idelalisib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Idelalisib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Idelalisib.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Idelalisib.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Idelalisib.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Idelalisib.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Idelalisib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Idelalisib.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Idelalisib.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Idelalisib.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Idelalisib.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Idelalisib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Idelalisib.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Idelalisib.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Idelalisib.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Idelalisib.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Idelalisib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Idelalisib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Idelalisib.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Idelalisib.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Idelalisib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Idelalisib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Idelalisib.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Idelalisib.Approved
RibociclibThe serum concentration of Ribociclib can be increased when it is combined with Idelalisib.Approved, Investigational
RifabutinThe serum concentration of Idelalisib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Idelalisib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Idelalisib can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Idelalisib.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Idelalisib.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Idelalisib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Idelalisib.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rindopepimut.Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Idelalisib.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Idelalisib.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Idelalisib.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Idelalisib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Idelalisib.Approved
RolapitantThe serum concentration of Idelalisib can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Idelalisib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Idelalisib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Idelalisib.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Idelalisib.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rotavirus Vaccine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Idelalisib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe metabolism of Rucaparib can be decreased when combined with Idelalisib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Idelalisib.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Idelalisib.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Idelalisib.Approved, Investigational
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Idelalisib.Approved
SalmeterolThe metabolism of Salmeterol can be decreased when combined with Idelalisib.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Idelalisib is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Idelalisib is combined with Salmonella typhi ty21a live antigen.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Idelalisib.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Idelalisib.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Idelalisib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Idelalisib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Idelalisib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Idelalisib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Idelalisib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Idelalisib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Idelalisib.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Idelalisib.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Idelalisib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idelalisib.Approved, Investigational
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Idelalisib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Idelalisib.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Idelalisib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Idelalisib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Idelalisib.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Idelalisib.Approved
SRP 299The risk or severity of adverse effects can be increased when Idelalisib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Idelalisib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Idelalisib can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Idelalisib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Idelalisib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Idelalisib.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Idelalisib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Idelalisib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Idelalisib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Idelalisib.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Idelalisib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Idelalisib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Idelalisib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Idelalisib.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Idelalisib.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Idelalisib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Idelalisib.Experimental
TecemotideThe risk or severity of adverse effects can be increased when Idelalisib is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Idelalisib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Idelalisib can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Idelalisib.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Idelalisib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Idelalisib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Idelalisib.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Idelalisib.Experimental
TeriflunomideThe serum concentration of Idelalisib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Idelalisib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Idelalisib.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Idelalisib.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Idelalisib.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Idelalisib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Idelalisib.Approved, Vet Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Idelalisib.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Idelalisib is combined with TG4010.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Idelalisib.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Idelalisib.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Idelalisib.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Idelalisib.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Idelalisib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Idelalisib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Idelalisib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Idelalisib.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Idelalisib.Approved, Withdrawn
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Idelalisib.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Idelalisib.Approved, Investigational
TofacitinibIdelalisib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Idelalisib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Idelalisib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Idelalisib.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Idelalisib is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Idelalisib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Idelalisib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Idelalisib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Idelalisib.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Idelalisib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Idelalisib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Idelalisib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Idelalisib.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Idelalisib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Idelalisib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Idelalisib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Idelalisib.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Idelalisib.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Idelalisib is combined with Typhoid Vaccine.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Idelalisib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Idelalisib.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Idelalisib.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Idelalisib.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
VandetanibThe metabolism of Vandetanib can be decreased when combined with Idelalisib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Idelalisib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Idelalisib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Idelalisib is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Idelalisib.Approved, Investigational
VemurafenibThe serum concentration of Idelalisib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Idelalisib.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Idelalisib.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Idelalisib.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Idelalisib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Idelalisib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Idelalisib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Idelalisib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Idelalisib.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Idelalisib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Idelalisib.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Idelalisib.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Idelalisib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Idelalisib.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Idelalisib.Approved
VoriconazoleThe serum concentration of Idelalisib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Idelalisib.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Idelalisib.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Idelalisib.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Idelalisib is combined with Yellow Fever Vaccine.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Idelalisib.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Idelalisib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Idelalisib.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Idelalisib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Idelalisib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Idelalisib.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Idelalisib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Idelalisib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Idelalisib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Idelalisib.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Idelalisib.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Idelalisib.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Jin F, Robeson M, Zhou H, Moyer C, Wilbert S, Murray B, Ramanathan S: Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol. 2015 Aug;55(8):909-19. doi: 10.1002/jcph.495. Epub 2015 May 6. [PubMed:25760671]
  2. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA: The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013. [PubMed:24376763]
  3. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE: Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10. [PubMed:24615776]
  4. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR: Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10. [PubMed:24615777]
External Links
KEGG Drug
D10560
PubChem Compound
11625818
PubChem Substance
310264996
ChemSpider
9800565
BindingDB
50403068
ChEBI
82701
ChEMBL
CHEMBL2216870
HET
40L
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Idelalisib
ATC Codes
L01XX47 — Idelalisib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
4xe0
FDA label
Download (496 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Follicular Lymphoma, Mantle Cell Lymphoma / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphoid Leukemia1
1CompletedTreatmentAgnogenic Myeloid Metaplasia1
1CompletedTreatmentAllergic Rhinitis (AR)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Indolent Non-Hodgkin's Lymphomas / Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia) / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Non-Hodgkin (NHL) / Multiple Myeloma (MM)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentRecurrent Follicular Lymphoma1
1CompletedTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
1Not Yet RecruitingTreatmentB Cell Chronic Lymphocytic Leukemia / B Cells--Tumors / B Cells-Tumors / Follicular Lymphoma (FL) / Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL)1
1RecruitingTreatmentB-Cell Malignancies1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Mediastinal B-cell Lymphoma1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1TerminatedTreatmentPancreatic Ductal Adenocarcinoma1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Indolent Non-Hodgkin's Lymphomas / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastasis / Recurrences1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2CompletedTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentAmyloidosis1
2RecruitingTreatmentChronic Lymphocytic Leucemia1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentFollicular Lymphoma (FL) / Indolent Lymphoma / Lymphoma, B-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Non Hodgkin Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Transformed Lymphoma / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Nodal Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Recurrent Splenic Marginal Zone Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Nodal Marginal Zone Lymphoma / Refractory Small Lymphocytic Lymphoma / Refractory Splenic Marginal Zone Lymphoma / Richter's Syndrome / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
2SuspendedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentB-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentFollicular Lymphoma (FL) / Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL)1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Non-Hodgkin's Lymphoma (NHL) / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)2
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3RecruitingTreatmentFollicular Lymphoma (FL) / Small Lymphocytic Lymphoma (SLL)1
3TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)2
3TerminatedTreatmentIndolent Non-Hodgkin's Lymphomas2
4CompletedTreatmentLymphoid Malignancies1
Not AvailableApproved for MarketingNot AvailableChronic Lymphocytic Leukaemia (CLL)1
Not AvailableNot Yet RecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)1
Not AvailableRecruitingNot AvailableFollicular Non-Hodgkin's Lymphoma Refractory1
Not AvailableRecruitingBasic ScienceAbsence of Signs or Symptoms / B-cell Non-Hodgkin's Lymphomas / Digestive System Signs and Symptoms / Indolent Adult Non-Hodgkin Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral150 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral100 mg
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral150 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6949535No2001-04-242021-04-24Us
US6800620No2001-04-242021-04-24Us
US8980901No2005-05-122025-05-12Us
US9149477No2005-05-122025-05-12Us
US8138195No2001-04-242021-04-24Us
USRE44599No2005-07-212025-07-21Us
US8865730No2013-03-052033-03-05Us
US8637533No2001-04-242021-04-24Us
USRE44638No2005-08-052025-08-05Us
US8492389No2001-04-242021-04-24Us
US9469643No2013-09-022033-09-02Us
US9492449No2010-03-112030-03-11Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0255 mg/mLALOGPS
logP3.03ALOGPS
logP3.36ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)9.86ChemAxon
pKa (Strongest Basic)4.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.16 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.83 m3·mol-1ChemAxon
Polarizability41.41 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 6-alkylaminopurines. These are compounds that contain an alkylamine group attached at the 6-position of a purine. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
6-alkylaminopurines
Alternative Parents
Quinazolines / Secondary alkylarylamines / Pyrimidones / Aminopyrimidines and derivatives / Aryl fluorides / Benzene and substituted derivatives / Imidolactams / Vinylogous halides / Heteroaromatic compounds / Imidazoles
show 7 more
Substituents
6-alkylaminopurine / Diazanaphthalene / Quinazoline / Aminopyrimidine / Pyrimidone / Secondary aliphatic/aromatic amine / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Pyrimidine
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, secondary amino compound, aromatic amine, purines, quinazolines (CHEBI:82701)

Targets

1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
2. UDP-glucuronosyltransferase 1A4
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
3. UDP-glucuronosyltransferase 1A1
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da

Drug created on May 08, 2015 13:47 / Updated on July 16, 2018 21:26